From Termeer to scuttled Allergan deal, Lysosomal’s winding road continues with Bial takeout

A takeout by Bial brings to an end Lysosomal’s search for a partner to advance its Parkinson’s programs after Allergan turned down its option to acquire the biotech last year. 

Portugal-based Bial will acquire Lysosomal Therapeutics Inc.’s pipeline and R&D team in a deal worth up to $130 million and establish a research center — Bial Biotech Investments Inc. — in Cambridge, Mass., to focus on genetically-defined Parkinson’s. Details are not disclosed...